Impact of the duration of antiplatelet therapy after vertebrobasilar artery stent placement.
Sherigar
R
R
Bobba
R K
RK
Arsura
E L
EL
D001488:Basilar Artery / Q000601:surgery*; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications; D006973:Hypertension / Q000150:complications; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D015607:Stents / Q000009:adverse effects*; D013927:Thrombosis / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014715:Vertebrobasilar Insufficiency / Q000150:complications / Q000601:surgery
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D010959:Tissue Plasminogen Activator